Oncology Medical News about osteosarcoma growth;notch pathway;cell cycle regulation

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation
British Journal of Cancer, 05/22/09

Tanaka M et al. - In a study to determine how the Notch pathway is involved in the pathogenesis of osteosarcoma, it was concluded that inhibition of Notch pathway suppresses osteosarcoma growth by regulation of cell cycle regulator expression and that the inactivation of the Notch pathway may be a useful approach to the treatment of patients with osteosarcoma.

Methods

Expression of the Notch pathway molecules was investigated in osteosarcoma biopsy specimens and the effect of Notch pathway inhibition was examined.

Results

Real-time PCR revealed overexpression of Notch2, Jagged1, HEY1, and HEY2.
Notch1 and DLL1 were downregulated in biopsy specimens.
Notch pathway inhibition using γ-secretase inhibitor and CBF1 siRNA slowed the growth of osteosarcomas in vitro.
γ-secretase inhibitor-treated xenograft models exhibited significantly slower osteosarcoma growth.
Cell cycle analysis revealed that γ-secretase inhibitor promoted G1 arrest.
Real-time PCR and western blot revealed that γ-secretase inhibitor reduced the expression of accelerators of the cell cycle, including cyclin D1, cyclin E1, E2, and SKP2.
p21cip1 protein, a cell cycle suppressor, was upregulated by γ-secretase inhibitor treatment.

<< Previous
Tumor markers and rectal cancer: Support for an...

Next >>
Alternative implication of CXCR4 in JAK2/STAT3 activation in...